$CELZ News

Creative Medical Tech Q1 EPS $(0.38) Beats $(0.39) Estimate

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

Creative Medical Technology Announces Results From Pilot Study Of Ultrasome, Proprietary Cell-Free Regenerative Therapy For Treatment Of Osteoarthritis Of Knee

Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long

Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Creative Medical Announces Interim 180-Day Follow-Up Data From FDA-Cleared ADAPT Clinical Trial Evaluating CELZ-201, Proprietary Perinatal Tissue-Derived Cell Therapy For Chronic Lower Back Pain

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

Creative Medical Technology Holdings shares are trading higher after the company received regulatory clearance for its BioDefense burn pit program and said no additional fundraising is required to execute the initiative.

Creative Medical Technology Holdings shares are trading higher after the company received regulatory clearance for its BioDefense burn pit program and said no additional fundraising is required to execute the initiative.

Creative Medical Technology Says No Additional Fundraising Is Required To Execute Initiative

Creative Medical Technology Holdings Receives Regulatory Clearance For Its BioDefense Inc. Burn Pit Program

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Creative Medical Technology Completes Patient Enrollment In FDA-Cleared ADAPT Clinical Trial For CELZ-201

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

Creative Medical Technology Holdings Says WHO Assigns "Olastrocel" As International Non-Proprietary Name For Lead Cell Therapy CELZ-201

Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now

Market Sentiment Around Loss-Making Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

Creative Medical Technology Launches National BioDefense Inc. Veterans Initiative To Combat Burn Pit Exposure Using AI And Regenerative Cell Therapy